New research shows that healthcare professionals consider a company’s leadership in a specific disease area and its overall reputation to be influential in prescribing decisions.

The lift is based on new research showing that the previous adverse effects in laboratory rats may not have been caused by the drug itself.

Eli Lilly has entered into a research collaboration with Genetic Leap, a private company focused on AI, to advance the development of RNA-based genetic medicines.  

NICE recommends an oral therapy for adults with PNH, marking the 1000th medicine evaluated since its inception in 1999.

It’s been both a good and bad week for French pharmaceutical company Sanofi, as their MS drug candidate, received mixed trial results.

The FDA has formally approved Emergent BioSolutions’ smallpox and mpox vaccine for use in preventing the virus in people at high risk of infection. 

The deal centres on Lindy’s microglassification technology, which facilitates high-concentration subcutaneous injections of biologic drugs.

The UK Government has launched a £400m public-private investment initiative, aiming to advance the pharmaceutical and life sciences sectors.